Bli medlem
Bli medlem

Du är här

2016-10-18

ExpreS2ion Biotechnologies: ExpreS2ion announces the initiation of a Phase I/IIa clinical trial for a new blood-stage malaria vaccine

Horsholm, Denmark, October 18, 2016 - Today, ExpreS2ion Biotech
Holding AB ("ExpreS2ion") announces that its collaboration partner,
the Jenner Institute of the University of Oxford, initiates a Phase
I/IIa clinical trial to assess the safety, immunogenicity, and
efficacy of the blood-stage Plasmodium falciparum malaria antigen
RH5.1, which is produced in ExpreS2ion's proprietary platform,
ExpreS2.

The Vaccine

RH5.1 is a novel, recombinant malaria antigen developed at the Jenner
Institute. It is based on recombinant RH5.1 protein produced in the
ExpreS2 platform using Drosophila Schneider 2 cells. RH5.1 is a part
of a larger protein complex expressed by the malaria parasite during
infection, helping it to invade red blood cells and causing the
disease. The RH5.1 vaccine is intended to block red blood cell
invasion and thus the progression of the disease.

The study

The present study is funded by Leidos Inc as part of the company's
prime contract
(http://investors.leidos.com/phoenix.zhtml?c=193857&p=irol-newsArticle&ID...)
with the United States Agency for International Development (USAID)
for the creation and testing of malaria vaccines. The clinical trial
will include 36-48 healthy UK volunteers. The initial purpose is to
assess the safety of the vaccine and the extent of the immune
response, as well as to identify the optimal dosing regimen of the
vaccine. A following step of the trial will test how effective the
vaccine is at preventing malaria by comparing individuals from this
study given the best dose of the vaccine will be compared to subjects
who have not received the vaccine, when challenged with malaria
parasites. The first part of the study will run for at least one
year.

Background

Malaria is a major global problem, with 3.2 billion people living at
risk of malaria infection. In 2015, malaria was thought to have
caused 438,000 deaths, most of which (70%) occurred in children under
five years old. Currently, there is no generally approved vaccine
available for malaria, which means that there is a great need for a
safe, effective malaria vaccine.

The Jenner Institute and the University of Oxford

The Jenner Institute is a research partnership between the University
of Oxford and the Pirbright Institute focused on the development of
vaccines against major global diseases. The University of Oxford's
Medical Sciences Division is one of the largest biomedical research
centres in Europe. The University is rated as the best in the world
and it has one of the largest clinical trial portfolios in the UK and
great expertise in taking discoveries from the laboratory into the
clinic.

CEO Steen Klysner comments

"It is a pleasure to announce the initiation of the blood stage
malaria clinical trial by such a highly esteemed collaboration
partner, and we are proud that the ExpreS2 platform has become an
enabling technology for this exciting project."

Certified Advisor

Sedermera Fondkommission is appointed as Certified Adviser for
ExpreS2ion.

For further information, please contact:

ExpreS2ion Biotechnologies, Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com (sk@expres2ionbio.com)

This press release contains information that ExpreS2ion is obligated
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication through the agency of the
contact person set out above at 10.00 CET, October 18, 2016.

About ExpreS2ion

ExpreS2ion Biotechnologies ApS, is a fully owned Danish subsidiary of
ExpreS2ion Biotech Holding AB with company register number
559033-3729. The subsidiary has developed a unique platform
technology, ExpreS2, enabling cost effective development and robust
production of complex proteins for new vaccines and diagnostics for
e.g. Malaria and Zika. Since founded in 2010, the company has used
its patented ExpreS2 platform to produce more than 200 proteins in
collaborations with research institutions and biopharmaceutical
companies, with a superior efficiency and success rate.

-----------------------------------------------------------
http://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces...
http://mb.cision.com/Main/14402/2103095/576272.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.